Global Database
Find medicine equivalents across 40+ countries — brand names, availability, and regulatory information worldwide.
The same medicine compound may have different brand names, formulations, and prescription requirements in different countries. Always consult a local healthcare provider when using medications abroad.
Regulator: MHRA
BNF (British National Formulary) is the standard prescribing reference. NHS formulary determines covered medications.
Regulator: Health Canada
Many US brand names available in Canada. Compendium of Pharmaceuticals and Specialties (CPS) is the reference. Some medicines available OTC in Canada that are prescription-only in USA.
Regulator: TGA
Therapeutic Goods Administration (TGA) regulates medications. PBS (Pharmaceutical Benefits Scheme) subsidizes many medications.
Regulator: EMA
EMA (European Medicines Agency) provides centralized approval across EU member states. Brand names may vary by country within EU.
Regulator: PMDA
PMDA (Pharmaceuticals and Medical Devices Agency). Japan often has different brand names; generic market smaller than Western countries.
Regulator: CDSCO
CDSCO (Central Medicines Standard Control Organization). India is a major generic medicine manufacturer. Many medications available without prescription. Costs significantly lower.
| Generic Name | 🇺🇸 USA | 🇬🇧 UK | 🇨🇦 Canada | 🇦🇺 Australia | 🇪🇺 EU |
|---|---|---|---|---|---|
| Acetaminophen | Tylenol | Paracetamol (Panadol) | Tylenol | Panadol | Paracetamol |
| Ibuprofen | Advil / Motrin | Nurofen | Advil | Nurofen | Nurofen / Brufen |
| Omeprazole | Prilosec | Losec / Mepradec | Losec | Losec | Losec / Omeprazole |
| Atorvastatin | Lipitor | Lipitor | Lipitor | Lipitor | Lipitor / Torvast |
| Fluoxetine | Prozac | Prozac / Fluoxetine | Prozac | Lovan / Prozac | Prozac / Fluctin |
| Sertraline | Zoloft | Lustral | Zoloft | Zoloft | Zoloft / Lustral |
| Sildenafil | Viagra | Viagra (OTC since 2018) | Viagra | Viagra | Viagra / Revatio |
| Metformin | Glucophage | Glucophage / Metformin | Glucophage | Glucophage | Glucophage / Metformin |
Medicine regulation varies significantly around the world. While most developed nations have robust systems for ensuring medicine safety and efficacy, the processes, timelines, and outcomes often differ. Understanding these differences is essential for healthcare providers treating international patients, travelers who need medications abroad, and patients researching treatment options.
The U.S. Food and Medicine Administration is widely considered the world's most rigorous medicine regulatory agency. The FDA approval process requires large Phase III randomized controlled trials demonstrating both safety and efficacy. FDA-approved medicines are often used as the international "gold standard" that other regulators look to, though other agencies conduct independent reviews.
The FDA operates several expedited pathways for serious conditions: Fast Track, Breakthrough Therapy designation, Accelerated Approval, and Priority Review. These have become increasingly important for oncology medicines and rare diseases.
The European Medicines Agency provides centralized medicine approvals valid across all EU member states. The EMA and FDA have historically shown high concordance in approval decisions, but the EMA has sometimes approved medicines that the FDA rejected (or vice versa), reflecting different assessments of benefit-risk profiles.
Post-Brexit, the UK's MHRA now operates independently from the EMA, though it frequently converges on similar decisions. The UK introduced an Innovative Licensing and Access Pathway (ILAP) to compete with EU approval timelines.
When traveling internationally with prescription medications, it is essential to: carry medications in their original labeled containers, bring a letter from your physician, carry no more than a 3-month supply, and research the destination country's regulations. Controlled substances (opioids, benzodiazepines, stimulants) face the strictest regulations and may require import permits for some countries. Some medications legal in the US are controlled substances or even illegal in other countries.
Medications available by prescription in the US may be available OTC in other countries, and vice versa. For example, sildenafil (Viagra) became available OTC in the UK in 2018 but remains prescription-only in the US. Codeine is available in low-dose OTC preparations in Canada. Conversely, some herbal products freely sold in the US are classified as medicines and regulated strictly in EU countries.
Health Canada: Canada's federal regulatory agency for medicines, medical devices, and food. The Health Products and Food Branch oversees medicine approvals through Health Canada's Therapeutic Products Directorate. Canada often approves medications shortly after FDA approval. The Notice of Compliance system tracks approved medications. Canada operates a parallel public-private healthcare system with provincial drug coverage programs.
Therapeutic Goods Administration (TGA) - Australia: Australia's national regulatory authority for therapeutic goods including medicines, medical devices, and other therapeutic products. The Australian Register of Therapeutic Goods (ARTG) lists all approved products. The Pharmaceutical Benefits Scheme (PBS) provides government-subsidized medications. Australia's regulations have unique requirements including scheduling levels for medicines (Schedules 1-9).
Pharmaceuticals and Medical Devices Agency (PMDA) - Japan: Japan's medicine regulatory agency, often considered alongside the FDA and EMA as one of three major global regulators. Japan has accelerated drug approval pathways and is part of the International Council for Harmonisation (ICH) along with FDA and EMA.
National Medical Products Administration (NMPA) - China: China's medicine regulator (formerly CFDA). Has undergone significant reform to align more with international standards. China has the world's second largest pharmaceutical market and provides important regulatory framework for Chinese traditional medicine alongside Western pharmaceuticals.
Central Drugs Standard Control Organization (CDSCO) - India: India regulates the world's largest generic drug manufacturing industry. India is "the pharmacy of the world" producing 40% of generic drugs used in the US. CDSCO has been increasing regulatory rigor to maintain export markets to developed countries.
National Health Service Approvals - United Kingdom: Post-Brexit, the MHRA (Medicines and Healthcare products Regulatory Agency) operates independently from the EMA. The Innovative Licensing and Access Pathway (ILAP) provides expedited approval for new medications. The NHS, through NICE (National Institute for Health and Care Excellence), determines which medications are covered.
The World Health Organization plays a crucial role in international medicine coordination through several mechanisms:
Generic drug manufacturing has become globalized, with India and China dominating production. India produces approximately 20% of global generic medicines and supplies 40% of generic medications used in the United States. China supplies most of the world's active pharmaceutical ingredients (APIs). This globalization has reduced medication costs but created supply chain vulnerabilities and quality control challenges.
The COVID-19 pandemic highlighted these vulnerabilities. Shortages of various medications occurred when supply chains were disrupted. Many countries are now reconsidering domestic manufacturing capacity and stockpiling strategies. The FDA has increased scrutiny of foreign manufacturers and has placed many on import alert lists when quality issues are identified.
Counterfeit medications represent a serious global health threat, particularly in developing countries. The WHO estimates that up to 10% of medications worldwide are counterfeit, with rates higher in some regions. Counterfeit drugs may contain wrong ingredients, wrong doses, dangerous contaminants, or no active ingredient at all. Antimalarials, antibiotics, lifestyle drugs (erectile dysfunction medications), and cancer treatments are frequently counterfeited.
Combating counterfeits requires international cooperation, technology (track-and-trace systems, holograms), patient education, and enforcement. Operation Pangea, an annual INTERPOL-coordinated operation, targets online pharmacies selling counterfeit medications. Patients can protect themselves by using legitimate pharmacies, being wary of unusually low prices, examining packaging carefully, and reporting suspicious products.
Medical tourism — traveling to other countries for healthcare — has become a significant global industry. Reasons include lower costs, access to procedures not available domestically, shorter waiting times, and combining travel with treatment. Common destinations include India, Thailand, Mexico, Costa Rica, Turkey, and various Eastern European countries.
Considerations for medical tourists include:
Americans often purchase medications from Canadian or Mexican pharmacies due to lower prices. While technically illegal under FDA regulations, the FDA has generally not enforced this for personal use quantities (typically up to 90-day supplies). Some considerations:
Generic drug names follow International Nonproprietary Names (INN) assigned by WHO. While most countries use INN names, the United States often uses United States Adopted Names (USAN) which may differ slightly. For example, "paracetamol" (INN, used internationally) is "acetaminophen" (USAN) in the United States. Other examples include lidocaine/lignocaine, epinephrine/adrenaline, and meperidine/pethidine. These naming differences can cause confusion for travelers and immigrants.
Brand names vary even more dramatically. The same medication can have completely different brand names across countries, often based on marketing decisions by manufacturers. The MedCentralHub International Database helps decode these differences.
Vaccine recommendations vary by country and disease prevalence. Travelers need to research destination-specific vaccine requirements and recommendations. The CDC provides comprehensive travel health information. Common travel vaccines include hepatitis A and B, typhoid, yellow fever (required for some countries), Japanese encephalitis, rabies, and meningitis. Some destinations require proof of specific vaccines (yellow fever certificate). Routine vaccines should be current before travel.
International cooperation in medicine regulation continues evolving. The International Council for Harmonisation (ICH) brings together regulators and pharmaceutical industries to develop common technical guidelines. Mutual recognition agreements (MRAs) between agencies reduce duplicate inspections. Common technical documents (CTD) standardize submission formats across major regulators.
Future developments may include increased real-world evidence acceptance, harmonized clinical trial standards, joint reviews for medicines treating global diseases, and integrated approaches to manufacturing inspections. These developments could speed access to important medications while maintaining safety standards globally.